In heart failure, the Arg16Gly and Gln27Glu polymorphisms of the b 2 -adrenoreceptor (b 2 -AR) gene are associated with exercise-capacity, clinical outcomes and response to b-AR blocker therapy. Whether b 2 -AR gene variants mediate these effects in-part through an impact on cardiac structural remodeling and pump function independent of the effects of b-blockers is uncertain. We evaluated whether the Arg16Gly and Gln27Glu variants of the b 2 -AR gene predict left ventricular ejection fraction (LVEF) and LV end diastolic diameter (LVEDD) in patients with idiopathic dilated cardiomyopathy (IDC) before and 6 months after receiving standard medical therapy other than b-AR blockers. In all, 394 patients with IDC and 393 age and gender-matched controls were genotyped for the b 2 -AR gene variants using restriction-fragment length polymorphism-based techniques. LVEF and dimensions were determined in 132 patients (of whom 71 were newly diagnosed) both at baseline and after 6 months. Genotype of neither variant was associated with the presence of IDC. Moreover, b 2 -AR genotype did not determine LVEF or LV dimensions prior to initiating therapy. After 6 months of therapy, LVEF increased by 7.171.0 absolute units (Po0.0001) and LVEDD decreased by 0.2770.06 cm (Po0.02). Adjusting for baseline values as well as gender, age, and type of angiotensin-converting enzyme inhibitor therapy received, genotype was associated with neither final LVEF and LVEDD, nor change in LVEF and LVEDD. In conclusion, these data suggest that in heart failure, the functional Arg16Gly and Gln27Glu variants of the b 2 -AR gene have no independent effect on adverse structural remodeling and pump function.
Introduction
Through a multitude of cardiac effects, including apoptosis 1 and necrosis, 2 persistent b-adrenoreceptor (b-AR) activation determines progressive heart failure. 3, 4 Although there is substantial evidence to implicate the b 1 -AR subtype in evolving cardiac dysfunction, 5 the role of the b 2 -AR is uncertain. 6 As selective b 1 -AR downregulation occurs in heart failure, the b 2 -AR may play an increasingly important role in cardiac disease. 7 Like the b 1 -AR, the b 2 -AR mediates contractile effects, 4, 6 but in contrast to the b 1 -AR, which is proapoptotic, the b 2 -AR is antiapoptotic. 1 In transgenic animals, although a 15-fold increase in b 1 -AR expression results in heart failure, 5 a substantially greater increase (60-fold) in b 2 -AR expression does not produce the same effects. 8 Hence, it may be argued that increased b 2 -AR activation in heart failure could be protective.
The activity of b 2 -ARs is determined in part by functional variants within the gene encoding the receptor. [9] [10] [11] [12] Both an Arg16Gly and a Gln27Glu polymorphism of the b 2 -AR gene influence the degree of agonist-stimulated receptor downregulation. 9 The potential role that b 2 -AR activation has in heart failure 1, 4, 6 has prompted a number of investigators to explore the impact of Arg16Gly and a Gln27Glu polymorphisms in cardiac disease. [13] [14] [15] [16] [17] [18] [19] In this regard, b 2 -AR genotypes resulting in enhanced agonist-stimulated receptor downregulation 9 are associated with, or show trends for an association with the progression to hospitalization, death or transplantation, 14, 15 a reduced exercise capacity, 16 and left ventricular (LV) functional responses to b-blocker therapy. 17 However, the mechanisms of b 2 -AR genotype effects in heart failure [14] [15] [16] [17] are uncertain. b 2 -AR genotype-dependent antiapoptotic actions 1 could produce distinct clinical outcomes through the well recognized impact of apoptosis on structural remodeling and cardiac function. 20, 21 Although some studies have reported on a lack of impact of b 2 -AR genotypes on baseline LV dimensions and pump function, [14] [15] [16] the data are difficult to interpret for a number of reasons. These studies were crosssectional rather than prospective analyses, conducted in patients with diverse cardiac pathologies and performed in patients of whom a proportion were receiving b-AR blocker therapy. [14] [15] [16] In contrast, some studies have shown b 2 -AR genotype-specific effects on LV structure and function after b-AR blocker therapy. 16, 17 However, whether the genetic effects noted in these studies 16, 17 were determined by independent actions of b 2 -AR genotype, or interactions between genotype and the well known effects of b-AR blockers on b-AR function, 3, 4 is not clear. Therefore, in the present study, to assess whether b 2 -AR genotypes determine LV dimensions and pump function independent of b-AR blockers, we evaluated the relationship between Arg16Gly and Gln27Glu polymorphisms of the b 2 -AR gene and LV dimensions and systolic function in patients with idiopathic dilated cardiomyopathy (IDC) before and 6 months after receiving medical therapy other than b-AR blockers.
Results

Demographic and general clinical data
No significant differences were noted in the demographic or general clinical data in genotype-specific subgroups of patients on whom LV structure and function was determined (Table 1) , except for an increase in the mean duration of disease in the Glu27 vs Gln27Glu and Gln27 groups (Table 1) .
Association between b 2 -AR genotype and IDC Both the case and the control groups were estimated to be in Hardy-Weinberg equilibrium. The w 2 values when comparing expected and actual genotype numbers were 5.53 and 4.48 for the case and the control groups, respectively, for the Arg16Gly variant of the b 2 -AR gene, and 1.51 and 0.12, respectively, for the Gln27Glu variant of the b 2 -AR gene. Four of the eight possible haplotypes were common in our subjects (Table 2) .
No differences were noted in the allele or haplotype frequencies between case and control groups (Table 2) . b 2 -AR genotype was not an independent predictor of IDC when considering the impact of Arg16Gly and Gln27Glu polymorphisms independently (logistic regression: Arg16Gly variant: GG vs CC; b-coefficient ¼ À0.2370.28, P ¼ 0.41; GC vs CC; b-coefficient ¼ À0.0970.25, P ¼ 0.71: Gln27Glu variant: CC vs GG; b-coefficient ¼ 0.8170.56, P ¼ 0.14; GC vs GG; b-coefficient ¼ 0.9170.57, P ¼ 0.11) or when constructing haplotypes for the two polymorphisms (logistic regression of Gly16Gly þ Gln27Gln haplotype vs other haplotypes: b-coefficient ¼ À0.1770.22, P ¼ 0.45). (Table 3 ) or as haplotypes (Table  4) . At the end of the study, b 2 -AR genotype failed to predict LV function and cavity dimensions irrespective of whether the Arg16Gly and the Gln27Glu polymorphisms of the b 2 -AR gene were considered separately (Table 3) or as haplotypes (Table 4) .
Discussion
The main findings of the present study are that the Arg16Gly and the Gln27Glu polymorphisms of the b 2 -AR gene, failed to predict LV systolic performance and cavity dimensions before and after 6 months of standard medical therapy in patients with IDC not receiving b-AR blockers. These data are the first to provide insight into the independent effect of b 2 -AR genotypes on LV dimensions and systolic function in chronic heart failure. Previous data suggesting a lack of impact of b 2 -AR genotypes on LV dimensions and systolic function in chronic heart failure [14] [15] [16] 18 are difficult to interpret, as these studies were confined to cross-sectional analyses, [14] [15] [16] conducted in patients with diverse cardiac pathologies, 15, 16 and performed in patients of whom a proportion were receiving b-AR blocker therapy. [14] [15] [16] In contrast, in the present study, patients in whom b 2 -AR genotypic effects on LV function and dimensions were determined, suffered from IDC only and were prospectively assessed for a 6-month-period during which time they were not receiving b-blocker therapy. 
275 (70) 107 (27) 11 (3) 657 (84) 129 ( 16 clinical outcomes 14, 15 and LV functional responses to bblocker therapy. 17 Alternatively, one previous study reported no association between b 2 -AR genotype and LV functional responses to b-blocker therapy. 18 The lack of an independent effect of b 2 -AR genotype on LV structure and function, as observed in the present study, would suggest that the b 2 -AR genotype-specific effects reported on in prior studies [14] [15] [16] [17] cannot be attributed to an independent effect of b 2 -AR genotype on LV structure and hence function. Alternative mechanisms must therefore be sought to explain these data. [14] [15] [16] [17] If not attributed to LV structural remodeling and hence pump function; an impact of b 2 -AR genotype on exercise performance, 16 could be attributed to b 2 -ARmediated vascular or inotropic responsiveness; and an association or trend for an association between b 2 -AR genotypes and clinical outcomes including death, hospitalization and transplantation, 14, 15 may be related to arrhythmic effects, 22 or b 2 -AR-mediated vascular responsiveness (action on LV afterload). b 2 -AR genotype-dependent LV functional responses to b-blocker therapy 17 may be through an impact of b 2 -AR genotype on the ability of b-blocker therapy to produce beneficial cardiac effects.
The Arg16Gly and Gln27Glu polymorphisms frequently occur together, hence in the present study we examined the possible effects that these polymorphisms may have in combination. Haplotypes were constructed and patients with the Gly16Gly þ Gln27Gln haplotype (i.e. patients expressing receptors in which both are highly sensitive to downregulation) were compared to other haplotypes. Previously a decreased exercise capacity has been reported in patients who are homozygous Gly16 and Gln27 compared to other homozygous combinations. 16 However, in the present study haplotype analysis did not reveal an association between b 2 -AR genotype and LV function and cavity dimensions at either baseline or follow-up. Post hoc analysis of the change in LVEF of 8.0% (n ¼ 16) vs 6.6% (n ¼ 97) revealed that sample numbers of 1154 would be required in each haplotype group in order to show that this difference in LVEF between the haplotype groups is significant (Po0.05) with 80% power. Hence this small difference in LVEF between the two haplotype groups is unlikely to be of clinical relevance.
The potential limitations of the present study are as follows. First, prospective follow-up was for only 6 months. However, this period was selected as beyond 6 months mortality and morbidity related to heart failure would have limited our ability to appropriately assess LV structural and functional changes. 23 Second, the time course of the history of the disease varied considerably between genotype groups. However, those patients with the risk allele (Gln27) had the shorter duration of disease and tended to have the higher final LVEF. Moreover, in the data analysis duration of disease was included as a potential confounder. Third, LV structure and function were only assessed at rest rather than during exercise. It is therefore possible that we could have missed an impact of b 2 -AR genotype on systolic function during exercise. However, our hypothesis was based on the antiapoptotic effects of the b 2 -AR 1 as apoptosis results in a loss of myocardial units, with subsequent cardiac dilatation and pump dysfunction, even at rest. 21 As cardiac dilatation influences systolic function at rest, the lack of a relationship between genotype and systolic function in the present study, supports our null hypothesis. Last, although we assessed two functional polymorphisms of the b 2 -AR gene, previous studies have shown that the functional Thr164Ile polymorphism of the b 2 -AR gene is also associated with exercise capacity 16 and the progression to death and transplantation. 15 However, based on the distribution of the alleles previously reported on for the Thr164Ile polymorphism, 15 we would have required 539 patients to show a 10 point difference in radionuclide LVEF between groups with 80% power after 6 months of therapy. Consequently, this was not a polymorphism that could be assessed in a single-centre study such as ours.
In conclusion, the present study indicates that the functional Arg16Gly and Gln27Glu variants of the b 2 -AR gene have no independent effect on adverse structural remodeling and pump function in patients with IDC. The relationship between these genotypes and progression to hospitalization, death or transplantation, 14,15 a reduced exercise capacity, 16 and left ventricular (LV) functional responses to b-blocker therapy 17 as previously described is therefore unlikely to be attributed to an independent effect of genotype on cardiac chamber dimensions and pump function.
Methods
Study groups
This study was approved by the Committee for Research on Human Subjects of the University of the Witwatersrand (approval number: M951122). The clinical component of the study was conducted between 1995 and 2001 when the use of b-AR blockers was not considered standard therapy for heart failure in South Africa. All patients gave informed consent before study entry. To ensure that b 2 -AR gene polymorphisms were not associated with IDC in this population, a case-control study was performed in which 394 patients with IDC and 393 age-matched control subjects of the same ethnic origins (African ancestry) were recruited. Subjects in the control group had a greater body mass index, higher blood pressures and consisted of more females (Table  5) . Patients were recruited if they were X18 and p70 years of age, in stable NYHA functional class (FC) I to IV heart failure of unknown etiology, had a left ventricular ejection fraction (LVEF) o40% as determined by radionuclide ventriculography, and had high-quality echocardiographic images with a LV end diastolic diameter (LVEDD) 45.5 cm. Exclusion criteria included evidence of another cause of heart failure and the presence of arrhythmias that could alter LVEF.
After initial presentation, and following a diagnosis by clinical examination and echocardiography (screening visit), 176 of the 394 patients agreed to participate in a prospective study assessing the impact of b 2 -AR gene polymorphisms on LV dimensions and function. During Adrenergic gene variants and heart failure D Badenhorst et al the 6-month-period of follow-up 24 patients died and 20 were lost to follow-up. Of the remaining 132 patients who were followed prospectively, 71 were newly diagnosed. This subgroup of IDC patients on whom follow-up LV structure and function was assessed were comparable in their demography and clinical characteristics to those of the total group of IDC patients assessed (Table 5) . These 132 patients who were followed prospectively received treatment with digoxin and diuretics (furosemide) for 7 days and then angiotensin-converting enzyme inhibitors (ACEI) were added to their therapy. These patients were followed for 6 months. Monthly visits were scheduled for clinical assessment and evaluation of patient's adherance to therapeutic agents. Clinical examinations, echocardiographic assessments and radionuclide studies were performed at baseline, and then repeated at 6 months. The primary end points were LVEF determined using radionuclide ventriculography and LV end diastolic diameter (LVEDD) determined using echocardiography. Radionuclide ventriculography as opposed to echocardiopgraphy was used as the method of preference to assess the impact of b 2 -AR genotype on LV systolic function as this measurement is not subject to observer bias. To show a 10-point difference in radionuclide LVEF between groups with 80% power after 6 months of therapy required a sample size in each group of 21 patients.
Functional class, echocardiography and radionuclide studies A physician assessed the NYHA functional class of the patients during the baseline and follow-up visits. The same physician evaluated all patients. A multiple gated equilibrium cardiac blood pool scintigraphic technique was used to measure LVEF (Elscint Apex 409). 24 Imaging was performed in the left anterior oblique projection providing the best septal separation of the ventricles with a 0-101 caudal angulation. Calculations of LV performance were made as previously described 25 using an automatic edge detection algorithm for the determination of LV borders. A single observer interpreted all studies. Two-dimensional targeted M-mode echocardiography with doppler color flow mapping was performed using a Hewlett Packard Sonos 5500 echocardiograph attached to a 2.5 or 3.5 MHz transducer. All studies were performed and interpreted by the same operator and recorded on videotape. Left ventricular dimensions were measured according to the American Society of Echocardiography guidelines. 26 Measurements of LV dimensions and function were determined on an average of X3 beats. The investigators that performed and interpreted the radionuclide and echocardiographic studies were unaware of the treatment assigned to patients.
Genotyping
Blood for genetic studies was obtained during the initial screening period. Deoxyribonucleic acid (DNA) was extracted from whole blood using standard techniques as previously described. 27 Genotyping was performed by an investigator unaware of the identity of the patient's from whom DNA was obtained. Genotyping was undertaken after the clinical component of the study was complete. Genotyping of the Arg16Gly and Gln27Glu variants of the b 2 -AR gene was undertaken using polymerase chain reaction (PCR)-restriction fragment length polymorphism-based techniques employing the appropriate primer pairs and restriction enzymes. DNA was amplified using 5 0 -GCCTTCTTGCTGGCACCCCAT-3 0 and 5 00 -CAGACGCTC GAACTTGGCCATG-3 0 forward and reverse primers, respectively. PCR was carried out in a total volume of 20 ml containing B50 ng DNA, 1 Â PCR buffer (Takara Bio Inc., Shiga, Japan), 2 mM MgCl 2 , 0.2 mM dNTP, 2.5 mM forward and reverse primers, 3% dimethylsulfoxide, 1 mg ml À1 bovine serum albumin and 1 U Taq polymerase (Takara). The PCR conditions were as follows: 941C for 4 min, followed by 30 cycles of denaturation (941C for 1 min per cycle), annealing (63.81C for 45 s) and extension (721C for 1 min) with a final extension step at 721C for 4 min. PCR resulted in a 168 base pair (bp) product. Genotyping of the Arg16Gly polymorphism was performed after 7 ml of PCR product was digested with 2.8 U of NcoI (Roche Diagnostics, Mannheim, Germany) at 371C overnight. NcoI cleaves 22 bp from the 3 0 end of both alleles and 18 bp from the 5 0 end of the Gly 16 allele. Hence, homozygotes for the Gly 16 allele were identified by the presence of a 128 bp product, homozygotes for the Arg 16 allele by the presence of a 146 bp product and heterozygotes by the presence of both a 128 and 146 bp product. Genotyping of the Gln27Glu polymorphism was performed after 7 ml of PCR product was digested with 555.5 U of BbvI (New England Biolabs Inc., Beverly, MA, USA) at 371C for 2 h. BbvI cleaves the Gln 27 allele to produce a 63 and a 105 bp fragment. Homozygotes for the Glu 27 allele were identified by the presence of a 168 bp product alone. Heterozygotes were identified by the presence of a 168, 105 and 63 bp fragment. Electrophoresis was performed on 4% agarose gels and banding patterns visualized with ethidium bromide staining and ultraviolet illumination. To avoid misgenotying as a consequence of failure of restriction enzyme digestion, a known heterozygous sample for each of the polymorphisms was included in each PCR, digestion procedure and gel. Furthermore, all samples that were homozygous Glu27 were reanalyzed. Despite repeated attempts one patient could not be genotyped for the Gln27Glu polymorphism.
Analysis
Data are presented as mean7s.e.m. Case and control group mean values were compared with the use of a two-sample Student's t-test or a Mann-Whitney test (depending on whether variables were nominal or ordinal (Bartlett's test)). To test for Hardy-Weinberg equilibrium the expected genotype numbers were calculated from the allele frequencies and deviation from the observed genotype numbers determined using a w 2 -test. Haplotypes of the Arg16Gly and Gln27Glu polymorphisms were assigned in individuals who were homozygous for both polymorphisms or heterozygous for only one of the polymorphism (controls: n ¼ 323; IDC all: n ¼ 332; IDC prospective analysis: n ¼ 114). In haplotype analysis subjects homozygous for the Gly16 and Gln27 alleles were compared with the other haplotypes present as the Gly16Gly þ Gln27Gln haplotype has previously been shown to be associated with differences in exercise performance. 16 Effects of alleles on the presence of IDC were evaluated using a w 2 -test. Genotype effects on the presence of IDC were assessed with logistic regression analysis with age, gender and body mass index (BMI) included as covariates. To assess the effect of genotype on either LVEF or cardiac dimensions, a MANCOVA was performed with age, gender, disease duration and BMI included in the regression model. A paired Student's t-test was used to detect changes from baseline. Analysis of covariance adjusting for baseline data, age, gender, disease duration and type of ACEI was employed to determine differences in changes in LV cavity size and function, and final LV cavity size and function between genotype groups. Genotype effects on final LV cavity size and function were assessed using MANCOVA with age, gender, BMI, disease duration and baseline data included as covariates. All probability values were adjusted for multiple genotyping.
